Corcept Therapeutics said Sept. 23, 2026 that Sean Maduck will retire as president of the company’s endocrinology division, ending a 14-year run leading the business. Justin Gunn will take over the role and assume full responsibilities Oct. 1, joining Corcept’s executive team and reporting to CEO Joseph K. Belanoff.
Maduck will stay on as a senior commercial advisor during the transition.
Gunn comes to the endocrinology job after joining Corcept in July 2024 as vice president of sales and commercial learning for the oncology division. In that role, he built a new field sales and training organization to support the launch of Lifyorli, Corcept’s treatment for platinum-resistant ovarian cancer.
Before Corcept, Gunn spent nearly 18 years at Gilead Sciences, where he led commercial sales teams across cardiovascular disease, respiratory disease, oncology and virology. He also held earlier marketing and sales roles at Merck and Sepracor.
Corcept said it has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists over more than 25 years focused on cortisol modulation. The company is running advanced clinical trials in hypercortisolism, solid tumors, ALS and liver disease. Today the company's shares have moved -3.67% to a price of $113.195. For more information, read the company's full 8-K submission here.
